You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFRvIII

Showing 1 - 25 of 61
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Glioblastoma Trial (Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T

Not yet recruiting
  • Recurrent Glioblastoma
  • Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection
  • (no location specified)
Apr 4, 2023

Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant Trial in Jyväskylä, Oulu, New Delhi (EGFRvIII-specific hinge-optimized

Active, not recruiting
  • Glioblastoma
  • +2 more
  • EGFRvIII-specific hinge-optimized CD3 ζ-stimulatory/41BB-co-stimulatory Chimeric Antigen Receptor autologous T-lymphocytes
  • Jyväskylä, Finland
  • +2 more
Sep 30, 2021

Glioblastoma Trial in Philadelphia (CART-EGFRvIII T cells, Pembrolizumab)

Completed
  • Glioblastoma
  • CART-EGFRvIII T cells
  • Pembrolizumab
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Mar 2, 2021

Glioblastoma or Malignant Glioma Trial in Worldwide (AMG 596, AMG 404)

Completed
  • Glioblastoma or Malignant Glioma
  • AMG 596
  • AMG 404
  • Los Angeles, California
  • +9 more
Dec 21, 2021

Brain Cancer, Brain Stem Tumors, Pontine Tumors Trial in Stanford (Rindopepimut)

Terminated
  • Brain Cancer
  • +2 more
  • Rindopepimut
  • Stanford, California
    Stanford University School of Medicine
Sep 20, 2021

Glioblastoma, Brain Tumor, Recurrent Trial in Spain (PF-299804 (Dacomitinib))

Completed
Has Results
  • Glioblastoma
  • Brain Tumor, Recurrent
  • PF-299804 (Dacomitinib)
  • Badalona, Barcelona, Spain
  • +11 more
Jul 2, 2021

Subjects Treated With CARv3-TEAM-E T Cells

Not yet recruiting
  • Glioblastoma Recurrent, EGFR vIII Mutant
  • +2 more
  • Disease assessments
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Aug 23, 2021

Glioblastoma, Gliosarcoma Trial in Durham (EGFRvIII CAR T cells)

Terminated
Has Results
  • Glioblastoma
  • Gliosarcoma
  • EGFRvIII CAR T cells
  • Durham, North Carolina
    The Preston Robert Tisch Brain Tumor Center at Duke
Jul 8, 2020

Esophagus Cancer, Hepatoma, Glioma Trial in Zhengzhou (CAR-T/TCR-T cells immunotherapy)

Unknown status
  • Esophagus Cancer
  • +3 more
  • CAR-T/TCR-T cells immunotherapy
  • Zhengzhou, Henan, China
    Henan Provincial People's Hospital
Feb 3, 2021

Malignant Glioma, Glioblastoma, Brain Cancer Trial run by the NCI (Epidermal growth factor receptor(EGFRv)III Chimeric antigen

Completed
Has Results
  • Malignant Glioma
  • +3 more
  • Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 16, 2019

Glioblastoma, Malignant Glioma, Recurrent Glioblastoma Trial in Boston (CARv3-TEAM-E T cells)

Not yet recruiting
  • Glioblastoma
  • +3 more
  • CARv3-TEAM-E T cells
  • Boston, Massachusetts
    Massachusetts General Hospital Cancer Center
Dec 13, 2022

Patients With Residual or Reccurent EGFRvIII+ Glioma Trial in San Francisco, Philadelphia (CART-EGFRvIII T cells)

Terminated
  • Patients With Residual or Reccurent EGFRvIII+ Glioma
  • CART-EGFRvIII T cells
  • San Francisco, California
  • +1 more
Mar 1, 2019

Malignant Glioma, Brain Tumor, Recurrent Trial in Durham (D2C7-IT)

Active, not recruiting
  • Malignant Glioma
  • Brain Tumor, Recurrent
  • Durham, North Carolina
    Preston Robert Tisch Brain Tumor Center at Duke
Jul 12, 2022

Glioma, Malignant Glioma of Brain, Recurrence Tumor Trial in Beijing (chimeric antigen receptor T cells)

Recruiting
  • Glioma
  • +2 more
  • chimeric antigen receptor T cells
  • Beijing, China
    Xuanwu Hospital
Jun 12, 2021

Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified

Completed
  • Subjects Entering Into This Protocol Will be Followed for up to 15 Years After Initial CART-EGFRvIII Infusion
    • San Francisco, California
    • +1 more
    Jan 28, 2019

    Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma Trial in United States (Bevacizumab, Rindopepimut (CDX-110) with

    Completed
    • Glioblastoma
    • +6 more
    • Birmingham, Alabama
    • +44 more
    Feb 12, 2020

    Glioblastoma Multiforme of Brain, Glioblastoma Multiforme Trial in Shenzhen (Antigen-specific IgT cells)

    Enrolling by invitation
    • Glioblastoma Multiforme of Brain
    • Glioblastoma Multiforme
    • Antigen-specific IgT cells
    • Shenzhen, Guangdong, China
    • +1 more
    Nov 23, 2021

    Malignant Glioma, Glioblastoma Trial in Durham (hEGFRvIII-CD3 (BRiTE), Activated Cell Therapy)

    Not yet recruiting
    • Malignant Glioma
    • Glioblastoma
    • hEGFRvIII-CD3 (BRiTE)
    • Activated Cell Therapy
    • Durham, North Carolina
      Duke University Medical Center
    Jun 24, 2022

    Glioblastoma, Brain Cancer, Brain Tumor Trial in New York (Intra-arterial Cetuximab, Intra-arterial Mannitol)

    Recruiting
    • Glioblastoma
    • +6 more
    • Intra-arterial Cetuximab
    • Intra-arterial Mannitol
    • New York, New York
      Lenox Hill Brain Tumor Center
    Oct 27, 2021

    Glioblastoma Trial in Worldwide (RO7428731)

    Recruiting
    • Glioblastoma
    • Melbourne, Victoria, Australia
    • +4 more
    Aug 2, 2022

    Brain Cancer Trial in Basking Ridge, Commack, New York (erlotinib, Cytoreductive Surgery)

    Completed
    • Brain Cancer
    • Basking Ridge, New Jersey
    • +3 more
    Jan 6, 2021

    Malignant Glioma Trial in Durham (D2C7-IT (6920 ng/mL via convection-enhanced delivery), Atezolizumab (1200 mg every three

    Recruiting
    • Malignant Glioma
    • D2C7-IT (6920 ng/mL via convection-enhanced delivery)
    • +2 more
    • Durham, North Carolina
      Duke University Medical Center
    Mar 22, 2022

    Glioma Trial in Boston (Supplemental High Fat Low Carbohydrate (sHFLC) + KetoPhyt)

    Not yet recruiting
    • Glioma
    • Supplemental High Fat Low Carbohydrate (sHFLC) + KetoPhyt
    • Boston, Massachusetts
      Tufts Medical Center
    Dec 8, 2022

    Glioblastoma Multiforme Trial in Baltimore (Dichloroacetate (DCA), Genotype)

    Recruiting
    • Glioblastoma Multiforme
    • Dichloroacetate (DCA)
    • Genotype
    • Baltimore, Maryland
      Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Aug 26, 2022

    Glioblastoma Multiforme Trial in Maastricht (Chloroquine, Radiotherapy, Temozolomide)

    Completed
    • Glioblastoma Multiforme
    • Maastricht, Netherlands
      Maastricht Radiation Oncology
    Jan 22, 2020